Zacks Research Analysts Lower Earnings Estimates for Danaher

Danaher Corporation (NYSE:DHR) – Equities researchers at Zacks Research lowered their FY2025 earnings per share estimates for shares of Danaher in a research report issued on Tuesday, November 11th. Zacks Research analyst Team now expects that the conglomerate will post earnings per share of $7.71 for the year, down from their previous estimate of $7.75. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s Q4 2025 earnings at $2.14 EPS and Q4 2026 earnings at $2.43 EPS.

DHR has been the topic of several other research reports. Wells Fargo & Company restated a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Robert W. Baird set a $247.00 target price on shares of Danaher in a research note on Wednesday, October 22nd. Barclays increased their target price on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Stock Up 2.8%

DHR stock traded up $6.12 during midday trading on Thursday, reaching $225.52. The company had a trading volume of 1,004,821 shares, compared to its average volume of 4,167,106. The company has a 50 day moving average of $204.76 and a two-hundred day moving average of $200.77. Danaher has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a market capitalization of $159.30 billion, a P/E ratio of 46.40, a PEG ratio of 3.28 and a beta of 0.81. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the business posted $1.71 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Insider Activity

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Pacific Capital Partners Ltd purchased a new position in shares of Danaher in the first quarter worth approximately $7,175,000. CWM LLC raised its position in Danaher by 36.9% in the first quarter. CWM LLC now owns 30,811 shares of the conglomerate’s stock worth $6,316,000 after purchasing an additional 8,313 shares in the last quarter. MQS Management LLC acquired a new stake in Danaher in the 1st quarter valued at $225,000. Sigma Planning Corp lifted its holdings in Danaher by 10.1% during the 1st quarter. Sigma Planning Corp now owns 11,279 shares of the conglomerate’s stock valued at $2,312,000 after purchasing an additional 1,036 shares during the last quarter. Finally, Wealthfront Advisers LLC increased its holdings in Danaher by 8.6% during the 1st quarter. Wealthfront Advisers LLC now owns 58,503 shares of the conglomerate’s stock valued at $11,993,000 after purchasing an additional 4,645 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.